DARA-IM: An Integrated In Silico Phase Ib/II Clinical Trial of Daraxonrasib Plus Ivermectin and Mebendazole Versus Daraxonrasib Monotherapy in Previously Treated Stage IV Pancreatic Cancer
Article type: Proposed research protocol and computational modelling framework
Research group: OneDayMD / SmartCancer Research Team
Protocol version: 1.2
Protocol date: 17 November 2026
Study designation: DARA-IM (Daraxonrasib–Ivermectin–Mebendazole)
Clinical setting: Second-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC)
Research design: Integrated Phase Ib/II virtual clinical trial
Abstract
Background
Metastatic pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge. Daraxonrasib, a RAS(ON) multi-selective inhibitor, has emerged as an important treatment option for previously treated metastatic pancreatic adenocarcinoma. Ivermectin and mebendazole have demonstrated experimental anticancer activity in selected preclinical models, but their clinical efficacy in PDAC remains unestablished.
Objective
To develop an integrated in silico Phase Ib/II research framework investigating whether the addition of ivermectin and mebendazole to daraxonrasib could provide incremental antitumour activity compared with daraxonrasib monotherapy in previously treated Stage IV PDAC.
Methods
A two-arm virtual clinical trial is proposed. Arm A receives daraxonrasib monotherapy. Arm B receives daraxonrasib combined with ivermectin and mebendazole, subject to pharmacokinetic and safety feasibility. The virtual population comprises adults with metastatic PDAC following one previous systemic chemotherapy line, irrespective of RAS/KRAS mutation status. Molecular stratification will include KRAS G12D, G12V, G12R, G12C, other RAS alterations and patients without a detectable RAS alteration. The computational framework integrates population pharmacokinetics, pharmacodynamics, tumour growth, drug synergy, resistance modelling, toxicity prediction and survival analysis.
Primary endpoint
Progression-free survival (PFS).
Secondary endpoints
Overall survival, objective response rate, duration of response, disease control rate, CA19-9 response, circulating tumour DNA response, quality of life and treatment-related toxicity.
Conclusion
DARA-IM provides a structured framework for investigating the biological plausibility, pharmacological feasibility and potential safety of combining daraxonrasib with two repurposed drugs. The combination should advance to clinical investigation only if clinically achievable exposures, reproducible additional antitumour activity and an acceptable safety profile can be established.
Keywords: pancreatic cancer; PDAC; metastatic pancreatic adenocarcinoma; daraxonrasib; RMC-6236; ivermectin; mebendazole; drug repurposing; RAS inhibition; in silico clinical trial; pharmacokinetics; precision oncology.
1. Introduction
1.1 The therapeutic challenge in metastatic pancreatic cancer
Pancreatic ductal adenocarcinoma is characterized by aggressive tumour biology, early metastatic dissemination, extensive molecular heterogeneity and a complex tumour microenvironment.
Although combination chemotherapy has improved outcomes, metastatic PDAC remains difficult to control. Resistance, disease progression, treatment toxicity and declining performance status frequently limit therapeutic options.
RAS signalling is particularly important in PDAC. KRAS mutations occur in the majority of pancreatic ductal adenocarcinomas and contribute to tumour proliferation, survival and resistance-associated signalling.
1.2 Daraxonrasib as the treatment backbone
Daraxonrasib (RASONQUE; formerly RMC-6236) is an oral RAS(ON) multi-selective inhibitor. It forms a tri-complex involving cyclophilin A and active GTP-bound RAS, disrupting interactions between RAS and downstream signalling effectors.
On 26 August 2026, the US Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.
In the randomized Phase 3 RASolute 302 study (NCT06625320), involving 500 previously treated patients, the overall-population results were:
| Outcome | Daraxonrasib | Chemotherapy |
|---|---|---|
| Median overall survival | 13.2 months | 6.7 months |
| Median progression-free survival | 7.2 months | 3.6 months |
| Objective response rate | 30% | 11% |
| OS hazard ratio | 0.40 | |
| PFS hazard ratio | 0.49 | |
These are observed results from RASolute 302, not predicted outcomes for DARA-IM. They provide the clinical benchmark for the proposed daraxonrasib monotherapy control arm.
Reference: FDA approval of daraxonrasib, 26 August 2026.
1.3 Rationale for investigating ivermectin
Ivermectin is an antiparasitic agent that has attracted experimental oncology interest because of reported effects on multiple cellular pathways, mitochondrial function, apoptosis and cellular transport mechanisms.
A 2022 pancreatic cancer study investigated ivermectin in patient-derived organoids and experimental pancreatic cancer models. Ivermectin inhibited organoid proliferation at experimental concentrations of 6 and 8 μM. The study also investigated combination treatment with gemcitabine and reported mitochondrial dysfunction and increased apoptosis.
These findings provide a preclinical rationale for additional investigation. They do not establish that ivermectin improves clinical outcomes in pancreatic cancer or that its effects are complementary to daraxonrasib.
1.4 Rationale for investigating mebendazole
Mebendazole is a benzimidazole antiparasitic drug with experimental microtubule-disrupting and antiproliferative properties.
Preclinical pancreatic cancer research has investigated mebendazole in genetically engineered KC and KPC mouse models. Reported findings included effects on tumour development, tumour burden, stromal desmoplasia and metastatic involvement.
The KPC model, which incorporates oncogenic KRAS and TP53 alterations, is particularly relevant to the molecular biology of PDAC. Nevertheless, animal-model results cannot be directly translated into human survival estimates.
1.5 Combination hypothesis
The proposed combination investigates three potentially complementary mechanisms:
| Agent | Experimental role | Research question |
|---|---|---|
| Daraxonrasib | RAS pathway inhibition | Does RAS suppression reduce tumour growth? |
| Ivermectin | Experimental signalling and mitochondrial effects | Does it provide additional tumour-cell inhibition? |
| Mebendazole | Microtubule disruption | Does it provide additional antiproliferative activity? |
The central hypothesis is that the additional agents may provide incremental anticancer activity or affect resistance mechanisms. Additive or synergistic effects must be demonstrated experimentally rather than assumed.
2. Study objectives
2.1 Primary objective
To determine whether adding ivermectin and mebendazole to daraxonrasib improves progression-free survival compared with daraxonrasib monotherapy.
2.2 Secondary objectives
- Evaluate overall survival.
- Compare objective response rate.
- Assess duration of response and disease control rate.
- Evaluate CA19-9 and circulating tumour DNA responses.
- Assess quality of life.
- Estimate grade 3–4 adverse events.
- Evaluate hepatotoxicity and neurological toxicity.
- Assess treatment interruptions and discontinuation.
- Characterize pharmacokinetic interactions between the three agents.
2.3 Exploratory objectives
- Investigate differences according to KRAS and other RAS mutation status.
- Identify potential biomarkers of response and resistance.
- Assess changes in RAS/MAPK signalling.
- Evaluate apoptosis and cell-cycle markers.
- Investigate tumour microenvironment and stromal characteristics.
- Examine whether previous chemotherapy influences subsequent treatment response.
3. Materials and Methods
3.1 Study design
DARA-IM is proposed as an integrated Phase Ib/II translational research programme consisting of:
- Phase Ib: Pharmacokinetic interaction, exposure feasibility, safety and tolerability investigation.
- Phase II: Randomized two-arm efficacy simulation comparing daraxonrasib monotherapy with the experimental three-drug combination.
The computational component will use synthetic patient profiles calibrated against published clinical evidence. Synthetic patients must be clearly distinguished from actual clinical participants.
3.2 PICO framework
| Population | Adults with Stage IV metastatic PDAC after one previous systemic treatment line. |
|---|---|
| Intervention | Daraxonrasib + ivermectin + mebendazole. |
| Comparator | Daraxonrasib monotherapy. |
| Primary outcome | Progression-free survival. |
| Secondary outcomes | Overall survival, ORR, duration of response, toxicity and quality of life. |
3.3 Patient eligibility
Inclusion criteria- Age 18 years or older.
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
- Stage IV metastatic disease.
- Documented progression after one previous systemic treatment line for metastatic disease.
- Previous fluoropyrimidine-based or gemcitabine-based treatment.
- ECOG performance status 0–1 for the primary model.
- Measurable disease according to RECIST 1.1.
- Adequate baseline organ function.
- Available tumour molecular profiling or validated circulating tumour DNA testing.
- Pancreatic neuroendocrine tumours and non-PDAC histologies.
- Previous daraxonrasib or relevant RAS(ON) inhibitor treatment.
- Uncontrolled hepatic dysfunction.
- Severe neurological conditions that complicate toxicity assessment.
- Unmanageable concomitant drug interactions.
- Pregnancy or breastfeeding.
Patients with actionable alterations requiring established biomarker-directed treatment should be assessed separately. The proposed research must not displace an indicated standard treatment.
3.4 Previous chemotherapy stratification
| Previous treatment | Stratum |
|---|---|
| FOLFIRINOX / modified FOLFIRINOX | Fluoropyrimidine-based |
| NALIRIFOX | Fluoropyrimidine-based |
| Gemcitabine + nab-paclitaxel | Gemcitabine-based |
| Other appropriate regimens | Other / exploratory |
3.5 Molecular stratification
The study includes all eligible Stage IV PDAC patients, irrespective of RAS mutation status. Molecular profiling will classify patients into:
- KRAS G12D.
- KRAS G12V.
- KRAS G12R.
- KRAS G12C.
- Other KRAS alterations.
- NRAS and HRAS alterations.
- No RAS alteration detected.
- Unknown or indeterminate molecular status.
Co-mutations including TP53, SMAD4, CDKN2A, BRCA1/2 and PALB2 will also be recorded.
RAS status, previous chemotherapy backbone and ECOG performance status should be considered for randomization stratification. Liver metastases should also be considered, subject to sample-size feasibility.
The primary efficacy analysis will include the entire eligible population. Molecular subgroup analyses will be exploratory unless independently powered.
3.6 Experimental treatment arms
Arm A — Active control
Daraxonrasib monotherapy.
Reference US prescribing-information regimen: 300 mg orally once daily until progression or unacceptable toxicity, subject to approved dose modifications.
Arm B — Experimental combination
Daraxonrasib + ivermectin + mebendazole.
Daraxonrasib provides the treatment backbone. Ivermectin and mebendazole are investigational additions. Their combination exposures must be established through pharmacokinetic and safety investigation before any efficacy expansion.
No ivermectin or mebendazole oncology dose is assumed in this protocol. Experimental anticancer concentrations must not be equated with safe human dosing.
4. Pharmacokinetic and Safety Assessment
4.1 Ivermectin exposure feasibility
Pancreatic cancer organoid experiments have reported ivermectin activity at 6–8 μM. The relevance of these concentrations to safe human plasma and tumour exposure is uncertain.
The model should evaluate Cmax, AUC, free-drug concentration, tumour penetration, CYP3A4 metabolism and P-glycoprotein transport.
4.2 Mebendazole exposure feasibility
A Phase 2a study in advanced gastrointestinal cancers attempted to achieve a serum mebendazole concentration of 300 ng/mL (approximately 1 μM). Despite individualized dosing, consistent achievement of the target concentration was difficult. All eight participants who underwent the eight-week tumour assessment had progressive disease.
These findings raise important questions about absorption, systemic availability and tumour penetration.
4.3 Drug interactions
Daraxonrasib is a CYP3A substrate and P-glycoprotein inhibitor. Ivermectin is affected by CYP3A4 metabolism and P-glycoprotein transport. The magnitude and clinical significance of any interaction in the proposed combination remain unknown.
Potential interactions must be investigated using validated pharmacokinetic models and appropriate laboratory and clinical studies. Dose separation alone must not be assumed to eliminate an interaction.
4.4 Safety monitoring
| Domain | Monitoring |
|---|---|
| Hepatic | ALT, AST, ALP, bilirubin |
| Renal | Creatinine, eGFR |
| Neurological | Neurological examination and symptom assessment |
| Haematological | Full blood count |
| Gastrointestinal | Nausea, vomiting, diarrhoea and abdominal symptoms |
| Dermatological | Rash, pruritus and skin toxicity |
| Cardiopulmonary | Symptoms of pneumonitis or other serious toxicity |
5. Phase Ib: Pharmacokinetic and Safety Investigation
5.1 Objectives
- Characterize pharmacokinetics of the combination.
- Identify clinically relevant drug interactions.
- Assess whether experimental anticancer exposures are achievable.
- Evaluate dose-limiting toxicities.
- Determine whether an acceptable combination exposure exists.
5.2 Proposed structure
| Parameter | Proposed design |
|---|---|
| Population | Previously treated metastatic PDAC |
| Backbone | Daraxonrasib |
| Experimental agents | Ivermectin and mebendazole |
| Initial safety window | 28 days, as a modelling assumption |
| Primary outcome | Dose-limiting toxicity and PK feasibility |
| Secondary outcome | Pharmacodynamic and preliminary tumour response |
A model-assisted Bayesian dose-escalation strategy may be evaluated. Sentinel exposure, staggered introduction where justified, predefined stopping rules and independent safety oversight are required for any actual human investigation.
The combination must not proceed to Phase II if safe and pharmacologically meaningful exposure cannot be demonstrated.
6. Phase II: Randomized Efficacy Investigation
6.1 Design
- Randomized, two-arm study.
- Open-label treatment assignment.
- 1:1 allocation.
- Blinded independent central radiology review.
- Intention-to-treat primary analysis.
- Molecularly stratified randomization.
6.2 Endpoints
Primary endpointProgression-free survival measured from randomization until radiological or clinical progression or death, according to the prespecified definition.
Secondary endpoints- Overall survival.
- Objective response rate according to RECIST 1.1.
- Duration of response.
- Disease control rate.
- CA19-9 response.
- Circulating tumour DNA response.
- Quality of life.
- Grade 3–4 adverse events.
6.3 Assessment schedule
| Assessment | Baseline | Every 4 weeks | Every 8 weeks |
|---|---|---|---|
| Clinical examination | Yes | Yes | |
| ECOG | Yes | Yes | |
| Blood count and chemistry | Yes | Yes | |
| CA19-9 | Yes | Yes | |
| ctDNA | Yes | Selected time points | |
| Pharmacokinetics | Yes | According to PK plan | |
| CT/MRI | Yes | Yes | |
| Quality of life | Yes | Yes |
7. Computational Methodology
7.1 Virtual patient generation
The model will initially generate 10,000 synthetic patient profiles per treatment arm for Monte Carlo uncertainty analysis. This number is a computational choice and does not represent actual clinical enrolment.
Each profile should contain:
- Demographics and body weight.
- ECOG performance status.
- Metastatic sites and tumour burden.
- KRAS, NRAS and HRAS mutation status.
- TP53, SMAD4 and CDKN2A alterations.
- Previous chemotherapy regimen and treatment response.
- Albumin, bilirubin, liver enzymes and renal function.
- Baseline CA19-9 and ctDNA.
- Relevant concomitant medications and pharmacokinetic factors.
7.2 Module 1: Tumour biology
The tumour model should include RAS signalling, MAPK activity, proliferation, apoptosis, tumour heterogeneity, stromal interactions and acquired resistance.
A simplified logistic tumour-growth equation is:
dT/dt = rT(1 − T/K) − E(t)T
Where T represents tumour burden, r represents intrinsic growth rate, K represents carrying capacity and E(t) represents treatment-associated tumour inhibition.
Treatment effects must be calibrated using experimental pharmacodynamic data rather than assumed clinical survival improvements.
7.3 Module 2: Pharmacokinetics
A simplified one-compartment oral model may be used initially:
dC/dt = (F × Dose/V) × Input(t) − (CL/V)C
Where F is bioavailability, V is apparent volume of distribution, CL is clearance and C is drug concentration.
The full model should incorporate absorption, protein binding, active metabolites, multiple compartments where supported and drug interactions.
Outputs include Cmax, Tmax, AUC, half-life, free drug concentration, interpatient variability and estimated tumour exposure.
7.4 Module 3: Drug synergy
Experimental concentration-response data should be used to evaluate combinations through:
- Bliss independence.
- Loewe additivity.
- Highest single agent analysis.
- Combination index.
Results from cell lines and organoids should be interpreted as preclinical evidence, not proof of clinical synergy.
7.5 Module 4: Toxicity
Adverse-event probabilities should be modelled according to drug exposure, baseline patient characteristics, organ function and concomitant medications.
The model should estimate the probability of Grade 3 or higher toxicity, hepatotoxicity, neurological events, gastrointestinal toxicity, treatment interruption and treatment discontinuation.
7.6 Module 5: Clinical outcomes
The final module should translate tumour response, resistance and toxicity into PFS, OS, ORR, duration of response and quality-adjusted survival.
8. Statistical Analysis Plan
8.1 Progression-free survival
The primary treatment comparison is expressed as:
HR(PFS) = hB(t) / hA(t)
Where hB(t) represents the progression hazard in Arm B and hA(t) represents the progression hazard in Arm A. An HR below 1 favours the experimental combination.
8.2 Overall survival
Overall survival is measured from randomization until death from any cause. Subsequent treatments, treatment discontinuation and crossover should be considered in the modelling framework.
8.3 Response rate
ORR = (CR + PR) / N evaluable × 100
DCR = (CR + PR + SD) / N evaluable × 100
CR represents complete response, PR partial response and SD stable disease.
8.4 Bayesian modelling
A Bayesian framework is appropriate because there are no established human efficacy estimates for ivermectin and mebendazole combined with daraxonrasib.
The prior for incremental combination efficacy should be conservative and centred on no additional benefit:
log(HR) ~ Normal(0, σ²)
Preclinical evidence may inform mechanistic assumptions and prior uncertainty, but must not be converted directly into favourable human hazard ratios. Case reports should not establish efficacy priors.
8.5 Sensitivity analysis
- No incremental effect from either repurposed drug.
- Incremental ivermectin effect only.
- Incremental mebendazole effect only.
- Additive combination effects.
- Synergistic combination effects.
- Increased toxicity or unfavourable drug interaction.
- RAS-mutated versus RAS-wild-type disease.
- Previous FOLFIRINOX versus gemcitabine-based chemotherapy.
- Liver-dominant versus non-liver-dominant disease.
- Different baseline performance and tumour burden categories.
8.6 Sample-size scenarios
Computational scenarios may examine 100, 150, 200 and 300 actual hypothetical clinical participants, with equal allocation between the two arms.
These are candidate simulation scenarios, not a final clinical sample-size recommendation. Final power calculations must incorporate the expected control-arm PFS, minimum clinically meaningful hazard ratio, type I error, power, accrual duration, follow-up, dropout and event requirements.
9. Model Calibration and Validation
The daraxonrasib control arm must reproduce established RASolute 302 outcomes before the experimental combination is evaluated.
| Calibration target | Published reference |
|---|---|
| Median OS, daraxonrasib | 13.2 months |
| Median PFS, daraxonrasib | 7.2 months |
| ORR, daraxonrasib | 30% |
| Median OS, chemotherapy | 6.7 months |
| Median PFS, chemotherapy | 3.6 months |
| ORR, chemotherapy | 11% |
These are calibration targets, not guaranteed simulation outputs.
Validation should include survival distribution reproduction, response-rate calibration, molecular subgroup assessment, alternative survival distributions, missing-data sensitivity and external validation.
10. Anticipated Results and Decision Framework
No experimental survival advantage should be reported before the computational model has been implemented and validated.
| Finding | Interpretation | Decision |
|---|---|---|
| No additional tumour inhibition | No incremental activity | Stop efficacy development |
| Activity only at unattainable exposure | Pharmacological infeasibility | Stop or redesign |
| Unacceptable toxicity | Unfavourable therapeutic window | Do not advance |
| Modest activity with acceptable exposure | Preliminary signal | Further translational work |
| Reproducible synergy with acceptable exposure | Stronger biological rationale | Consider clinical development |
11. Resistance Mechanisms and Translational Biomarkers
The study should investigate whether additional treatment effects could influence resistance to RAS inhibition.
Potential resistance mechanisms include MAPK reactivation, receptor tyrosine kinase feedback, alternative survival pathways, tumour heterogeneity and stromal-mediated resistance.
Exploratory biomarkers may include phosphorylated ERK, RAS pathway activity, apoptosis markers, cell-cycle activity, microtubule integrity and circulating tumour DNA.
Patient-derived organoids and serial molecular profiling could help determine whether the experimental agents provide reproducible additional pharmacodynamic activity.
12. Ethical and Regulatory Considerations
This is a proposed research protocol, not a treatment recommendation.
The combination is investigational and its safety with daraxonrasib has not been established. Any actual human investigation requires regulatory authorization, institutional research ethics approval, informed consent, clinical trial registration and independent safety monitoring.
The FDA approval of daraxonrasib applies to its defined US indication. Regulatory approval and access may differ in Malaysia and other jurisdictions.
13. Limitations
- Preclinical translation: Cell-line, organoid and animal findings do not necessarily predict human clinical efficacy.
- Exposure feasibility: Ivermectin and mebendazole may not achieve experimental anticancer concentrations safely in human tumours.
- Drug interactions: The combined pharmacokinetics of all three drugs remain insufficiently characterized.
- Molecular heterogeneity: PDAC includes different molecular and biological subgroups.
- Case-report bias: Patient reports are vulnerable to selection bias, confounding and incomplete documentation.
- Synthetic data limitations: A large simulated population cannot compensate for inadequate source data or incorrect model assumptions.
- External validity: Clinical trial populations may not fully represent routine oncology patients.
14. Conclusion
DARA-IM proposes a two-arm, second-line virtual clinical trial investigating whether ivermectin and mebendazole can provide additional anticancer activity when combined with daraxonrasib in metastatic pancreatic ductal adenocarcinoma.
Daraxonrasib provides a clinically validated treatment backbone. Ivermectin and mebendazole offer experimental mechanisms that justify further investigation but have not demonstrated clinical efficacy in this combination or established efficacy against metastatic PDAC.
The principal challenge is to establish whether the additional agents can achieve adequate tumour exposure at tolerable concentrations without compromising daraxonrasib exposure or increasing toxicity.
The integrated Phase Ib/II approach offers a structured framework for examining these questions.
15. References
- US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. 26 August 2026. FDA.
- US Food and Drug Administration. RASONQUE (daraxonrasib) Prescribing Information. Revised August 2026. Prescribing information.
- US Food and Drug Administration. NDA 220910: Multidisciplinary Review and Evaluation. Regulatory review.
- Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Frontiers in Pharmacology. 2022. doi:10.3389/fphar.2022.934746.
- A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports. 2021;11:8981. doi:10.1038/s41598-021-88433-y.
- Mebendazole pancreatic cancer preclinical research. PubMed literature search.
- RASolute 302, NCT06625320. ClinicalTrials.gov.
- RASolute 303, NCT07491445. ClinicalTrials.gov.
- OneDayMD. Stage 4 pancreatic cancer and fenbendazole: research and reported cases. OneDayMD.
- SmartCancer. Pancreatic cancer treatment: research and treatment strategies. SmartCancer.
Suggested citation: OneDayMD Research Team. DARA-IM: An Integrated In Silico Phase Ib/II Clinical Trial of Daraxonrasib Plus Ivermectin and Mebendazole Versus Daraxonrasib Monotherapy in Previously Treated Stage IV Pancreatic Cancer. Proposed research protocol. Version 1.0. 2026.
Research classification: Hypothesis-generating translational oncology protocol. No clinical trial results are reported.
.png)
Comments
Post a Comment